Neil Kale

Neil Kale

Graduate researcher at Carnegie Mellon University, exploring AI for healthcare.

Sitemap

A list of all the posts and pages found on the site. For you robots out there is an XML version available for digesting as well.

Pages

Posts

Future Blog Post

less than 1 minute read

Published:

This post will show up by default. To disable scheduling of future posts, edit config.yml and set future: false.

Blog Post number 4

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 3

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 2

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 1

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

portfolio

Dynamical systems approaches for deep learning

My undergraduate senior thesis from 2024 reimagines neural network designs as discrete dynamical systems, and investigates the effects of sparse and low-rank matrices on iterative network performance.

publications

Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune checkpoint inhibitors (ICI) in advanced solid tumors

Published in Journal of Clinical Oncology, 2022

This paper investigates the impact of CDKN2A and MTAP genomic alterations on the response to immune checkpoint inhibitors in cancer patients and finds that the co-occurrence of MTAP/CDKN2A alterations is associated with poorer outcomes, particularly in urothelial carcinoma and melanoma, accompanied by lower tumor-infiltrating lymphocyte density in melanoma samples with both alterations.

Recommended citation: Adib, E., Nassar, A., El Zarif, T., Kale, N., Rakaee, M., Mouhieddine, T. H., Abou Alaiwi, S., Freeman, D., Labban, M., Akl, E., Haddad, R. I., Hodi, F. S., Sonpavde, G. P., Giannakis, M., Braun, D. A., Gusev, A., Choueiri, T. K., Overstreet, E., Stone, E., & Kwiatkowski, D. J. (2022). "Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors." Journal of Clinical Oncology, 40(16_suppl), 2622–2622. https://doi.org/10.1200/jco.2022.40.16_suppl.2622

Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance

Published in Cancer Cell, 2023

Using clinical data on human melanoma and urothelial carcinoma and murine models, we show that MTAP deletion and accumulation of MTA lead to an immune cold microenvironment through effects on both PRMT5 and adenosine receptors.

Recommended citation: Gjuka, D., Adib, E., Garrison, K., Chen J., Zhang Y., Li W., Boutz D., Lamb C., Tanno Y., Nassar A., Zarif T., Kale N., Rakaee M., Mouhieddine T., Alaiwi A., Gusev A., Rogers T., Gao J., Georgiou G., Kwiatkowski D., Stone E. (2023). "Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance." Cancer Cell, 41. 1-14. https://doi.org/10.1016/j.ccell.2023.09.005

talks

teaching

Teaching experience 1

Undergraduate course, University 1, Department, 2014

This is a description of a teaching experience. You can use markdown like any other post.

Teaching experience 2

Workshop, University 1, Department, 2015

This is a description of a teaching experience. You can use markdown like any other post.